Shareholder wealth maximization, business ethics and social responsibility

Poitras, Geoffrey

doi:10.1007/bf00881581

Cited by 35 publications

(25 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous research centered on CSR-related decision making has focused largely on the influence of shareholders (McWilliams and Siegel, 2001) and customers (Luo and Bhattacharya, 2006). Such effects are consistent with the notion that Western managers seek to maximize shareholder wealth and make a profit by satisfying customer needs (Poitras, 1994). In contrast, our findings reveal a dominant role played by both shareholders and government in the minds of Chinese organizational decision makers.…”

Section: Research Implicationscontrasting

confidence: 43%

Opening the Black Box of CSR Decision Making: A Policy-Capturing Study of Charitable Donation Decisions in China

et al. 2014

View full text Add to dashboard Cite

This policy capturing study, conducted in China, investigated the cognitive basis of managerial decisions to make a corporate charitable donation, a global issue in the context of Corporate Social Responsibility (CSR) research and practice. Participants (N=376) responded to a series of scenarios manipulating pressure from the five stakeholders (government, customers, competitors, employees, and shareholders) most commonly addressed by CSR research. The independent variables examined included organizational factors (industry, ownership, previous company donation, firm size, firm age and perceived CEO attitudes toward charity) and the participants' personal values. Results indicate a large positive effect of shareholder and governmental pressure on the decision with lesser positive effects from customers and competitors. Surprisingly, employee pressure had a negative effect on the decision to make a charitable donation. Further, personal values and CEO attitudes toward charity were significantly related to the decisions participants made. In line with our theorizing, the findings indicate that a combination of personal, organizational, and institutional factors are salient in the minds of decision makers.

show abstract

Section: Research Implicationscontrasting

confidence: 43%

Opening the Black Box of CSR Decision Making: A Policy-Capturing Study of Charitable Donation Decisions in China

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In the U.S., this oversight includes the ethical approval process for medical research embodied in 45 CFR that empowers the Institutional Review Board (IRB). 3 Following Poitras (1994), the goal of SWM depends on the future common stock price and, as such, does not have ethical transparency. Some assumption about the efficiency of the stock market in valuing ethical concerns is required.…”

Section: Medical Ethics Bioethics and Business Ethicsmentioning

confidence: 99%

“…More precisely, the private sector firms conducting the bulk of medical R&D are motivated by the ethical standards of the marketplace (Poitras, 1994). 1 These standards differ from those of government which is an advocate for patients as well as having some control of the health care system through publicly funded medical care and drug plans.…”

Section: Medical Research and Development (Randd) Is An Areamentioning

confidence: 99%

Ethical Transparency and Economic Medicalization

Poitras

Meredith

2008

J Bus Ethics

Self Cite

View full text Add to dashboard Cite

show abstract

“…The goal of SWM depends on the future common stock price, and as such does not have ethical transparency. 11 Some assumption about the efficiency of the stock market in valuing ethical concerns is required. In this vein, the layers of regulatory oversight aimed to restrict unfettered corporate activity coming into play.…”

Section: Medical Ethics Business Ethics and Bioethicsmentioning

confidence: 99%

“…The third section of this paper examines general differences between medical ethics, as detailed by the American Medical Association (AMA), and business ethics, as reflected in the objective of corporate SWM. 11 The relevance of OxyContin abuse and diversion for the loosely defined subject of bioethics is also considered. The fourth section details the economic medicalization of addiction and substance abuse.…”

Section: Introductionmentioning

confidence: 99%

OxyContin, prescription opioid abuse and economic medicalization

Poitras¹

2012

Self Cite

View full text Add to dashboard Cite

This paper examines the relevance of OxyContin diversion and abuse to the economic medicalization of substance abuse and addiction. Given that medicalization is the general social process of nonmedical problems being transformed into medical problems, economic medicalization occurs where the motivation for the transformation is commercial profitability or, in a corporate context, achieving the objective of shareholder wealth maximization. After considering potential conflicts between medical ethics and business ethics, practical aspects of economic medicalization are detailed by considering the methods used to market OxyContin by Purdue Pharma. Illegal practices are identified and contrasted with legal practices that facilitated economic medicalization. Implications of medicalization research for designing public heath solutions to the epidemic of prescription opioid abuse are discussed.

show abstract

Shareholder wealth maximization, business ethics and social responsibility

Cited by 35 publications

References 35 publications

Opening the Black Box of CSR Decision Making: A Policy-Capturing Study of Charitable Donation Decisions in China

Opening the Black Box of CSR Decision Making: A Policy-Capturing Study of Charitable Donation Decisions in China

Ethical Transparency and Economic Medicalization

OxyContin, prescription opioid abuse and economic medicalization

Contact Info

Product

Resources

About